DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa + heptavalent pneumococcal conjugate vaccine, Prevenar
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Allogeneic Haematopoietic Stem Cell Transplantation
Conditions
Allogeneic Haematopoietic Stem Cell Transplantation
Trial Timeline
Sep 1, 2003 → Oct 1, 2006
NCT ID
NCT00169728About DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa + heptavalent pneumococcal conjugate vaccine, Prevenar
DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa + heptavalent pneumococcal conjugate vaccine, Prevenar is a phase 3 stage product being developed by Pfizer for Allogeneic Haematopoietic Stem Cell Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00169728. Target conditions include Allogeneic Haematopoietic Stem Cell Transplantation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00169728 | Phase 3 | Completed |
Competing Products
9 competing products in Allogeneic Haematopoietic Stem Cell Transplantation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ASP0113 | Astellas Pharma | Phase 2 | 52 |
| Valganciclovir + Ganciclovir | Roche | Phase 3 | 77 |
| Blinatumomab in combination with donor lymphocyte infusion | Amgen | Phase 2 | 51 |
| Denosumab | Amgen | Phase 2 | 51 |
| Inotuzumab Ozogamicin + Vincristine Sulfate Liposome | Pfizer | Phase 1/2 | 40 |
| Genotropin (Recombinant Human Growth Hormone) | Pfizer | Phase 1 | 32 |
| immunosuppression | Pfizer | Phase 2 | 51 |
| Mycophenolate Mofetil | Hikma Pharmaceuticals | Pre-clinical | 18 |
| Vancomycin Pre-Treatment + Vancomycin Placebo + SER-155 + SER-155 Placebo | Seres Therapeutics | Phase 1 | 25 |